APA (7th ed.) Citation

Li, Y., Cui, Q., Liu, S., Liu, L., Li, M., Gao, J., . . . Tang, X. (2024). Rituximab potentially improves clinical outcomes of CAR-T therapy for r/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion. Cellular Oncology, 47(5), 1649. https://doi.org/10.1007/s13402-024-00945-7

Chicago Style (17th ed.) Citation

Li, Yangzi, et al. "Rituximab Potentially Improves Clinical Outcomes of CAR-T Therapy for R/r B-ALL via Sensitizing Leukemia Cells to CAR-T-mediated Cytotoxicity and Reducing CAR-T Exhaustion." Cellular Oncology 47, no. 5 (2024): 1649. https://doi.org/10.1007/s13402-024-00945-7.

MLA (9th ed.) Citation

Li, Yangzi, et al. "Rituximab Potentially Improves Clinical Outcomes of CAR-T Therapy for R/r B-ALL via Sensitizing Leukemia Cells to CAR-T-mediated Cytotoxicity and Reducing CAR-T Exhaustion." Cellular Oncology, vol. 47, no. 5, 2024, p. 1649, https://doi.org/10.1007/s13402-024-00945-7.